About the Targeted Protein Degradation Summit
With clinical data showing clear signals of efficacy of PROTACs, increasing number of candidates accelerated towards clinical development and the rise of molecular glues unlike ever seen before, 2020 certainly was a promising year for the field of targeted protein degradation.
In the context of rapid progress and mounting desire to transform degrader tools into transformative therapies, the 4th Annual Targeted Protein Degradation (TPD) Summit will reunite large pharma, innovative biotechs and pioneering academics to discuss the full and comprehensive range of next generation protein degrading technologies to achieve efficient degradation of a broad range of disease-causing targets.
From optimizing PKPD, to overcoming innate and acquired resistance and enabling brain barrier penetration, the 4th Annual TPD Summit will be your most comprehensive guide to addressing the most unique challenges of next generation targeted protein degraders to power your strategies and pipelines towards achieving your 2021/2022 milestones.
Evaluate the exclusive updates of ongoing clinical trials to accelerate towards the first clinically approved therapy with insights from Kymera Therapeutics, Arvinas, Nurix Therapeutics & BMS
Deep dive into the methodologies of enhancing target engagement by improving target specificity, uncovering strategies to find novel ligases and modelling of covalency to develop next generation degraders with insights from Eli Lilly, FogPharma, GSK & Janssen
Review the plethora of disease indications that are being targeted by PROTACs and molecular glues including Alzheimers, Parkinsons, COVID-19 and AML with insights from Bristol Myers Squibb, Progenra & Origami Therapeutics
Explore the different approaches to penetrating the blood brain barrier, comparing and contrasting the discovery, development and optimization of PROTACs and molecular glues for neurodegenerative indications with insights from C4 Therapeutics & Progenra
Outline the core mechanisms of PROTAC resistance and the approaches to overcoming this to successfully progress through preclinical and clinical studies with insights from University of Dundee, Ranok Therapeutics & Captor Therapeutics